Clinical trials: Insulin
Type 2 Diabetes Mellitus, Metabolic Syndrome
Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome
This is a Phase 2, multi-center, double-blind, placebo-controlled study of the safety and effect of PBI-4050 at doses ranging from 400 mg to 1200 mg on relevant biomarkers in subjects with inadequately-controlled T2DMS on stable…
- Trial name
- NCT03081598
- Testing
- PBI-4050
- Where
- 11 sites in Canada
- Volunteers
- 104 people
- Sponsor
- Liminal BioSciences Ltd.
Diabetes Mellitus, Type 1
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
- Trial name
- CATT1 (NCT06334133)
- Testing
- Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- vTv Therapeutics
Diabetes, Healthy
Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to demonstrate bioequivalence between insulin detemir produced by the NN729 process and by the current process in healthy subjects.
- Trial name
- NCT01490099
- Testing
- insulin detemir
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 Diabetes
This study is conducted in Europe. The aim of this observational study is to document the glycaemic parameters, adverse events, including drug reactions, as well as hypoglycaemic episodes, in patients that switched from insulin…
- Trial name
- ProMix (NCT01536652)
- Testing
- biphasic insulin aspart 30
- Where
- Germany
- Volunteers
- 4,994 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion [CSII])…
- Trial name
- NCT01109316
- Testing
- Insulin lispro 2 day reservoir in-use, Insulin lispro 6 day reservoir in-use, Insulin aspart 6 day reservoir in-use
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin.
- Trial name
- NCT01476345
- Testing
- LY2963016, Lantus
- Where
- South Africa
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Insulin Glargine in Type 2 Diabetes
The aim of this project is to confirm the efficacy and safety profile of Insulin glargine in daily practice and to improve the physicians' knowledge and experience concerning Insulin glargine
- Trial name
- NCT00268645
- Testing
- Insulin Glargine
- Where
- Turkey (Türkiye)
- Volunteers
- 534 people
- Sponsor
- Sanofi
Healthy
A Crossover Study Assessing the Pharmacokinetics, Pharmacodynamics, and Safety of Recombinant Human Insulin
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, and safety of recombinant human insulin. The study will consist of 2 phases.
- Trial name
- NCT00358553
- Testing
- Insulin
- Where
- Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Baxter Healthcare Corporation
Type 2 Diabetes Mellitus
Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 Diabetes
Primary objective to evaluate the effect of a 12-week treatment period with prandial administration of Technosphere Insulin on glucose control in subjects with T2 DM.
- Trial name
- NCT00511602
- Testing
- Technosphere Insulin
- Volunteers
- 123 people
- Sponsor
- Mannkind Corporation
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin Analogues
This trial is conducted in Europe. The aim of this observational study is to evaluate the blood glucose control (HbA1c) using NovoRapid® (insulin aspart) and Levemir® (insulin detemir) after switch from human insulins for…
- Trial name
- NCT00873639
- Testing
- insulin aspart, insulin detemir
- Where
- Romania
- Volunteers
- 417 people
- Sponsor
- Novo Nordisk A/S
Healthy Subjects
Pharmacokinetic and Pharmacodynamic Effects of Insulex® R in Comparison to Humulin® R in Healthy Subjects
The goal of this clinical trial is to evaluate whether Insulex® R demonstrates similar pharmacokinetic (PK) and pharmacodynamic (PD) profiles compared to Humulin® R after a single subcutaneous dose of 0.3 units/kg in healthy…
- Trial name
- NCT07364669
- Testing
- Insulex® R (soluble human insulin, biosimilar), Humulin® R (soluble human insulin, biosimilar)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Laboratorios Pisa S.A. de C.V.
Type 1 Diabetes, Type 2 Diabetes
Closed Loop Glucose Control in a Simulated ICU Setting
This is a proof of concept safety study of a rule-based closed loop glucose control system designed for use in the intensive care unit setting.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Stress Induced Hyperglycemia
- Trial name
- NCT07646067
- Testing
- FUSION closed loop glucose control system
- Volunteers
- 6 people
- Sponsor
- Ideal Medical Technologies
Insulin Resistance
Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet).
- Trial name
- NCT00162799
- Testing
- Triflusal (DCI)
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- J. Uriach and Company
Diabetes Mellitus, Type 1
Tandem Freedom - Feasibility Trial 2
This feasibility study is a prospective, single arm study evaluating the Tandem Freedom system in adults with type 1 diabetes. Existing Control-IQ technology users will use Control-IQ technology at home for a one week run-in…
- Trial name
- NCT06834568
- Testing
- t:slim X2 insulin pump with Tandem Freedom Algorithm
- Where
- New Zealand
- Volunteers
- 10 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without metformin over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-L (NCT00715624)
- Testing
- Lixisenatide (AVE0010), Basal Insulin, Metformin
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 496 people
- Sponsor
- Sanofi
Type1 Diabetes
Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM
The aim of this trial is to demonstrate bioequivalence of Glaritus® to Lantus® with regard to its total and to its maximum serum insulin concentrations.
- Trial name
- NCT01357603
- Testing
- Glargine
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Wockhardt
Diabetes Mellitus, Type 2
Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.
Primary Objective: >To obtain an estimation for both treatment groups of the proportion of patients that reach the target of HbA1c <= 7% without confirmed nocturnal hypoglycaemia in each treatment group.
- Trial name
- DINAMO (NCT01122979)
- Testing
- INSULIN GLARGINE, NPH insulin (insulin isophane), INSULIN GLULISINE
- Where
- 10 sites in Brazil
- Volunteers
- 72 people
- Sponsor
- Sanofi
Hepatitis C, Chronic, Insulin Resistance
Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)
This is a Phase 3b/4, prospective, open-label, randomized, multicenter study of peginterferon alfa-2b plus ribavirin in participants with chronic hepatitis C, genotype 1.
- Trial name
- NCT00493805
- Testing
- Combination of pegylated interferon alfa-2b and ribavirin
- Volunteers
- 59 people
- Sponsor
- Merck Sharp & Dohme LLC
Growth Hormone Deficiency (GHD), Growth Hormone Deficiency in Children
GB06 Phase III Trial for Pediatric Growth Hormone Deficiency
This study aims to evaluate the efficacy and safety of GB06 (a biosimilar of Norditropin®FlexProTM from Novo Nordisk) for the treatment of growth disorders caused by growth hormone deficiency (GHD) in children.
- Conditions
- Growth Hormone Deficiency (GHD), Growth Hormone Deficiency in Children, Growth Hormone Deficiency, Pediatric
- Trial name
- NCT07553351
- Testing
- GB06, Norditropin®FlexProTM
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Kexing Biopharm Co., Ltd.
Diabetes Mellitus, Type 1
A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week
This study compares the new long-acting insulin 287 with the marketed insulin glargine for use in type 1 diabetes. The study will test how insulin is taken up in your blood, how long it stays there and how the blood sugar is…
- Trial name
- NCT03723772
- Testing
- Insulin icodec, IGlar U100
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Novo Nordisk A/S